Quarterly ResultMay 5, 2026, 07:08 AM
Editas Medicine Q1 Net Loss $25.0M; EDIT-401 on Track for Human PoC
AI Summary
Editas Medicine reported a net loss of $25.0 million, or $0.26 per share, for the first quarter of 2026, a significant improvement from $76.1 million in Q1 2025. The company continues to advance its lead candidate, EDIT-401, for hyperlipidemia, with preclinical data showing promising results and a first-in-human study on track for initiation this year, aiming for early human proof-of-concept data by year-end 2026. Additionally, the U.S. Patent and Trademark Office reaffirmed a decision favoring the Broad Institute in a key CRISPR/Cas9 patent interference case, which benefits Editas.
Key Highlights
- EDIT-401 on track for first-in-human study and early human proof-of-concept data by year-end 2026.
- Cash and cash equivalents were $123.6 million as of March 31, 2026, funding operations into Q3 2027.
- Net loss attributable to common stockholders was $25.0 million, or $0.26 per share, for Q1 2026.
- Net loss significantly decreased from $76.1 million ($0.92 per share) in Q1 2025.
- Research and development expenses decreased by $9.0 million to $17.6 million in Q1 2026.
- General and administrative expenses decreased by $3.1 million to $10.2 million in Q1 2026.
- U.S. Patent and Trademark Office reaffirmed decision favoring Broad Institute in CRISPR/Cas9 interference.
- No restructuring and impairment charges recorded in Q1 2026, compared to $40.9 million in Q1 2025.